humulin n- insulin human injection, suspension sterile diluent- diluent injection, solution
eli lilly and company - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - humulin n is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. humulin n is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.3)] , and - in patients who have had hypersensitivity reactions to humulin n or any of its excipients [see warnings and precautions (5.5)] . risk summary available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were not performed. the estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a hba1c >7% and has been reported to be as high as 20-25% in women with a hba1c >10%. the estimated background risk of miscarriage for the indicated population is unkn
humulin 70/30- insulin human injection, suspension
a-s medication solutions - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - humulin 70/30 is a fixed ratio premix recombinant human insulin formulation indicated to improve glycemic control in adult patients with diabetes mellitus. humulin 70/30 is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.3)], and - in patients who have had hypersensitivity reactions to humulin 70/30 or any of its excipients [see warnings and precautions (5.4)] . pregnancy category b risk summary all pregnancies have a background risk of birth defects, loss, or other adverse outcome regardless of drug exposure. this background risk is increased in pregnancies complicated by hyperglycemia and may be decreased with good metabolic control. it is essential for patients with diabetes or history of gestational diabetes to maintain good metabolic control before conception and throughout pregnancy. in patients with diabetes or gestational diabetes, insulin requirements may decrease during the first trimester, generally increase during the second and third trimesters, and rapidly de
humulin m3 (mixture 3) suspension for injection 100 iu/ml
eli lilly & co. limited - insulin human (rdna) - suspension for injection - insulin human (rdna) 100 iu - drugs used in diabetes
humulin s (soluble) solution for injection 100iu/ml
eli lilly & co. limited - insulin human (rdna) - solution for injection - insulin human (rdna) 100 iu - drugs used in diabetes
humulin s (soluble) 100iu/ml suspension for injection in cartridge
eli lilly nederland b.v papendorpseweg 83, 3528 bj, utrecht, nl-3991, netherlands - insulin human, rdna - solution for injection - insulin human (rdna) 100 iu - drugs used in diabetes
humulin m3 (mixture 3) 100iu/ml suspension for injection in cartridge
eli lilly nederland b.v papendorpseweg 83, 3528 bj, utrecht, nl-3991, netherlands - insulin human, rdna - suspension for injection - insulin human (rdna) 100 iu - drugs used in diabetes
velosulin
novo nordisk a/s - insulin human - diabetes mellitus - drugs used in diabetes - treatment of diabetes mellitus.
humulin n- insulin human injection, suspension
physicians total care, inc. - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - instructions for insulin vial use never share needles and syringes. correct syringe type doses of insulin are measured in units . u–100 insulin contains 100 units/ml (1 ml=1 cc). with humulin n, it is important to use a syringe that is marked for u–100 insulin preparations. failure to use the proper syringe can lead to a mistake in dosage, causing serious problems for you, such as a blood glucose level that is too low or too high. syringe use to help avoid contamination and possible infection, follow these instructions exactly. disposable syringes and needles should be used only once and then discarded by placing the used needle in a puncture-resistant disposable container. properly dispose of the puncture-resistant container as directed by your health care professional. preparing the dose - wash your hands. wash your hands. - carefully shake or rotate the bottle of insulin several times to completely mix the insulin. carefully shake or rotate the bottle of insulin several times to completely mi
novolin 70/30- human insulin injection, suspension
novo nordisk - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [usp'u] in 1 ml - novolin 70/30 is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. limitations of use: in novolin 70/30, the proportions of short-acting and intermediate-acting insulins are fixed and do not allow for basal versus prandial dose adjustments. novolin 70/30 is contraindicated: risk summary available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were not performed. the estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a hba1c >7 and has been reported to be as high as 20-25% in women with a hba1c >10. the estimated background risk of miscarriage for the indicated population is unknown. in the u.s. general
novolin n- human insulin injection, suspension
novo nordisk - insulin human (unii: 1y17cti5sr) (insulin human - unii:1y17cti5sr) - insulin human 100 [iu] in 1 ml - novolin n is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. novolin n is contraindicated: risk summary available data from published studies over decades have not established an association with human insulin use during pregnancy and major birth defects, miscarriage or adverse maternal or fetal outcomes (see data). there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations). animal reproduction studies were not performed. the estimated background risk of major birth defects is 6-10% in women with pre-gestational diabetes with a hba1c >7 and has been reported to be as high as 20-25% in women with a hba1c >10. the estimated background risk of miscarriage for the indicated population is unknown. in the u.s. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2-4% and 15-20%, respectively. clinical considerations diseas